Brown Advisory Inc Blueprint Medicines Corp Transaction History

Brown Advisory Inc

$77.3 Billion
Q3 2024

A detailed history of Brown Advisory Inc transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Brown Advisory Inc holds 593,768 shares of BPMC stock, worth $53.7 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares

593,768

Previous 617,992 3.92%

Holding current value

$53.7 Million

Previous $66.6 Million 17.58%

% of portfolio

0.07%

Previous 0.09%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$84.1 - $120.5 $2.04 Million - $2.92 Million	-24,224 Reduced 3.92%	593,768 $54.9 Million
Q2 2024 Aug 14, 2024	SELL	$85.18 - $108.78 $4.8 Million - $6.13 Million	-56,370 Reduced 8.36%	617,992 $66.6 Million
Q1 2024 Apr 24, 2024	SELL	$73.17 - $99.79 $406,678 - $554,632	-5,558 Reduced 0.82%	674,362 $64 Million
Q4 2023 Feb 08, 2024	BUY	$43.96 - $92.84 $1.71 Million - $3.61 Million	38,881 Added 6.07%	679,920 $62.7 Million
Q3 2023 Oct 24, 2023	BUY	$46.9 - $66.0 $274,036 - $385,638	5,843 Added 0.92%	641,039 $32.2 Million
Q2 2023 Jul 31, 2023	BUY	$42.2 - $66.37 $75,453 - $118,669	1,788 Added 0.28%	635,196 $40.1 Million
Q1 2023 May 08, 2023	BUY	$37.97 - $50.0 $1.22 Million - $1.61 Million	32,126 Added 5.34%	633,408 $28.5 Million
Q4 2022 Feb 13, 2023	SELL	$41.06 - $66.48 $15.2 Million - $24.6 Million	-370,712 Reduced 38.14%	601,282 $26.3 Million
Q3 2022 Nov 14, 2022	SELL	$49.93 - $77.7 $1.16 Million - $1.81 Million	-23,275 Reduced 2.34%	971,994 $64 Million
Q2 2022 Nov 14, 2022	BUY	$45.23 - $70.15 $2.22 Million - $3.44 Million	49,014 Added 5.18%	995,269 $50.3 Million
Q2 2022 Sep 13, 2022	BUY	$45.23 - $70.15 $28,268 - $43,843	625 Added 0.07%	960,269 $48.5 Million
Q2 2022 Aug 02, 2022	BUY	$45.23 - $70.15 $2.1 Million - $3.25 Million	46,351 Added 5.08%	959,644 $48.8 Million
Q1 2022 Nov 14, 2022	SELL	$54.1 - $110.08 $758,157 - $1.54 Million	-14,014 Reduced 1.46%	946,255 $60.4 Million
Q1 2022 Sep 13, 2022	SELL	$54.1 - $110.08 $5,896 - $11,998	-109 Reduced 0.01%	913,293 $58.3 Million
Q1 2022 May 09, 2022	BUY	$54.1 - $110.08 $2.01 Million - $4.09 Million	37,147 Added 4.24%	913,402 $58.6 Million
Q4 2021 Jan 27, 2022	BUY	$94.25 - $115.99 $2.55 Million - $3.14 Million	27,080 Added 3.19%	876,255 $93.9 Million
Q3 2021 Nov 12, 2021	BUY	$80.98 - $109.47 $4.32 Million - $5.84 Million	53,317 Added 6.7%	849,175 $87.3 Million
Q2 2021 Jul 29, 2021	BUY	$82.78 - $101.0 $3.23 Million - $3.94 Million	39,049 Added 5.16%	795,858 $70 Million
Q1 2021 May 14, 2021	BUY	$90.71 - $108.28 $1.83 Million - $2.18 Million	20,176 Added 2.74%	756,809 $73.6 Million
Q4 2020 Feb 12, 2021	BUY	$92.08 - $124.48 $1.32 Million - $1.79 Million	14,374 Added 1.99%	736,633 $82.6 Million
Q3 2020 Nov 16, 2020	BUY	$66.45 - $92.7 $716,530 - $999,584	10,783 Added 1.52%	722,259 $67 Million
Q2 2020 Aug 14, 2020	BUY	$57.09 - $79.27 $16 Million - $22.2 Million	279,501 Added 64.7%	711,476 $55.5 Million
Q1 2020 May 15, 2020	BUY	$48.11 - $82.22 $2.63 Million - $4.49 Million	54,602 Added 14.47%	431,975 $25.3 Million
Q4 2019 Feb 14, 2020	BUY	$66.73 - $82.59 $1.2 Million - $1.49 Million	17,981 Added 5.0%	377,373 $30.2 Million
Q3 2019 Nov 14, 2019	BUY	$72.9 - $101.41 $6.2 Million - $8.62 Million	85,048 Added 31.0%	359,392 $26.4 Million
Q2 2019 Aug 12, 2019	BUY	$73.54 - $97.8 $2.72 Million - $3.62 Million	36,972 Added 15.58%	274,344 $25.9 Million
Q1 2019 May 15, 2019	BUY	$48.7 - $86.6 $11.6 Million - $20.6 Million	237,372 New	237,372 $19 Million

Others Institutions Holding BPMC

# of Institutions

351

Shares Held

60.3M

Call Options Held

2.25M

Put Options Held

1.18M

View Full List

About Blueprint Medicines Corp

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

More about BPMC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Brown Advisory Inc, based on Form 13F filings with the SEC.

News

Stay updated on Brown Advisory Inc with notifications on news.

Account

Brown Advisory Inc Blueprint Medicines Corp Transaction History